Literature DB >> 28899014

Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levels.

Yo-El S Ju1,2, Sharon J Ooms3,4,5, Courtney Sutphen1,2, Shannon L Macauley1,2, Margaret A Zangrilli1, Gina Jerome1,2, Anne M Fagan1,2,6, Emmanuel Mignot7, John M Zempel1, Jurgen A H R Claassen3,4,5, David M Holtzman1,2,6.   

Abstract

See Mander et al. (doi:10.1093/awx174) for a scientific commentary on this article.Sleep deprivation increases amyloid-β, suggesting that chronically disrupted sleep may promote amyloid plaques and other downstream Alzheimer's disease pathologies including tauopathy or inflammation. To date, studies have not examined which aspect of sleep modulates amyloid-β or other Alzheimer's disease biomarkers. Seventeen healthy adults (age 35-65 years) without sleep disorders underwent 5-14 days of actigraphy, followed by slow wave activity disruption during polysomnogram, and cerebrospinal fluid collection the following morning for measurement of amyloid-β, tau, total protein, YKL-40, and hypocretin. Data were compared to an identical protocol, with a sham condition during polysomnogram. Specific disruption of slow wave activity correlated with an increase in amyloid-β40 (r = 0.610, P = 0.009). This effect was specific for slow wave activity, and not for sleep duration or efficiency. This effect was also specific to amyloid-β, and not total protein, tau, YKL-40, or hypocretin. Additionally, worse home sleep quality, as measured by sleep efficiency by actigraphy in the six nights preceding lumbar punctures, was associated with higher tau (r = 0.543, P = 0.045). Slow wave activity disruption increases amyloid-β levels acutely, and poorer sleep quality over several days increases tau. These effects are specific to neuronally-derived proteins, which suggests they are likely driven by changes in neuronal activity during disrupted sleep.
© The Author (2017). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  EEG; beta-amyloid; sleep; slow wave activity; tau

Mesh:

Substances:

Year:  2017        PMID: 28899014      PMCID: PMC5790144          DOI: 10.1093/brain/awx148

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  30 in total

1.  Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo.

Authors:  Randall J Bateman; Ling Y Munsell; John C Morris; Robert Swarm; Kevin E Yarasheski; David M Holtzman
Journal:  Nat Med       Date:  2006-06-25       Impact factor: 53.440

2.  Quantification of sleepiness: a new approach.

Authors:  E Hoddes; V Zarcone; H Smythe; R Phillips; W C Dement
Journal:  Psychophysiology       Date:  1973-07       Impact factor: 4.016

3.  Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.

Authors:  Courtney L Sutphen; Mateusz S Jasielec; Aarti R Shah; Elizabeth M Macy; Chengjie Xiong; Andrei G Vlassenko; Tammie L S Benzinger; Erik E J Stoops; Hugo M J Vanderstichele; Britta Brix; Heather D Darby; Manu L J Vandijck; Jack H Ladenson; John C Morris; David M Holtzman; Anne M Fagan
Journal:  JAMA Neurol       Date:  2015-09       Impact factor: 18.302

Review 4.  Sleep and Alzheimer disease pathology--a bidirectional relationship.

Authors:  Yo-El S Ju; Brendan P Lucey; David M Holtzman
Journal:  Nat Rev Neurol       Date:  2013-12-24       Impact factor: 42.937

5.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale.

Authors:  M W Johns
Journal:  Sleep       Date:  1991-12       Impact factor: 5.849

6.  Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers.

Authors:  Rachel Potter; Bruce W Patterson; Donald L Elbert; Vitaliy Ovod; Tom Kasten; Wendy Sigurdson; Kwasi Mawuenyega; Tyler Blazey; Alison Goate; Robert Chott; Kevin E Yarasheski; David M Holtzman; John C Morris; Tammie L S Benzinger; Randall J Bateman
Journal:  Sci Transl Med       Date:  2013-06-12       Impact factor: 17.956

7.  Effect of 1 night of total sleep deprivation on cerebrospinal fluid β-amyloid 42 in healthy middle-aged men: a randomized clinical trial.

Authors:  Sharon Ooms; Sebastiaan Overeem; Kees Besse; Marcel Olde Rikkert; Marcel Verbeek; Jurgen A H R Claassen
Journal:  JAMA Neurol       Date:  2014-08       Impact factor: 18.302

8.  Increased hypocretin-1 levels in cerebrospinal fluid after REM sleep deprivation.

Authors:  Mario Pedrazzoli; Vania D'Almeida; Paulo J F Martins; Ricardo B Machado; Lin Ling; Seiji Nishino; Sergio Tufik; Emmanuel Mignot
Journal:  Brain Res       Date:  2004-01-02       Impact factor: 3.252

9.  Neuronal activity regulates the regional vulnerability to amyloid-β deposition.

Authors:  Adam W Bero; Ping Yan; Jee Hoon Roh; John R Cirrito; Floy R Stewart; Marcus E Raichle; Jin-Moo Lee; David M Holtzman
Journal:  Nat Neurosci       Date:  2011-05-01       Impact factor: 24.884

10.  Neuronal activity regulates extracellular tau in vivo.

Authors:  Kaoru Yamada; Jerrah K Holth; Fan Liao; Floy R Stewart; Thomas E Mahan; Hong Jiang; John R Cirrito; Tirth K Patel; Katja Hochgräfe; Eva-Maria Mandelkow; David M Holtzman
Journal:  J Exp Med       Date:  2014-02-17       Impact factor: 14.307

View more
  114 in total

Review 1.  Establishing a framework for neuropathological correlates and glymphatic system functioning in Parkinson's disease.

Authors:  Saranya Sundaram; Rachel L Hughes; Eric Peterson; Eva M Müller-Oehring; Helen M Brontë-Stewart; Kathleen L Poston; Afik Faerman; Chloe Bhowmick; Tilman Schulte
Journal:  Neurosci Biobehav Rev       Date:  2019-05-24       Impact factor: 8.989

Review 2.  Disturbed sleep and diabetes: A potential nexus of dementia risk.

Authors:  Calliope Holingue; Alexandra Wennberg; Slava Berger; Vsevolod Y Polotsky; Adam P Spira
Journal:  Metabolism       Date:  2018-02-01       Impact factor: 8.694

Review 3.  Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factors.

Authors:  Chanung Wang; David M Holtzman
Journal:  Neuropsychopharmacology       Date:  2019-08-13       Impact factor: 7.853

Review 4.  Association between circadian rhythms and neurodegenerative diseases.

Authors:  Yue Leng; Erik S Musiek; Kun Hu; Francesco P Cappuccio; Kristine Yaffe
Journal:  Lancet Neurol       Date:  2019-02-12       Impact factor: 44.182

Review 5.  It's complicated: The relationship between sleep and Alzheimer's disease in humans.

Authors:  Brendan P Lucey
Journal:  Neurobiol Dis       Date:  2020-07-29       Impact factor: 5.996

Review 6.  Sleep as a Therapeutic Target in the Aging Brain.

Authors:  Thierno M Bah; James Goodman; Jeffrey J Iliff
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

Review 7.  Obstructive Sleep Apnea and Its Treatment in Aging: Effects on Alzheimer's disease Biomarkers, Cognition, Brain Structure and Neurophysiology.

Authors:  Anna E Mullins; Korey Kam; Ankit Parekh; Omonigho M Bubu; Ricardo S Osorio; Andrew W Varga
Journal:  Neurobiol Dis       Date:  2020-08-27       Impact factor: 5.996

Review 8.  The glymphatic pathway in neurological disorders.

Authors:  Martin Kaag Rasmussen; Humberto Mestre; Maiken Nedergaard
Journal:  Lancet Neurol       Date:  2018-11       Impact factor: 44.182

Review 9.  Understanding the impact of sex and gender in Alzheimer's disease: A call to action.

Authors:  Rebecca A Nebel; Neelum T Aggarwal; Lisa L Barnes; Aimee Gallagher; Jill M Goldstein; Kejal Kantarci; Monica P Mallampalli; Elizabeth C Mormino; Laura Scott; Wai Haung Yu; Pauline M Maki; Michelle M Mielke
Journal:  Alzheimers Dement       Date:  2018-06-12       Impact factor: 21.566

10.  Sleep and neuropsychological performance in HIV+ subjects on efavirenz-based therapy and response to switch in therapy.

Authors:  Cecilia M Shikuma; Lindsay Kohorn; Robert Paul; Dominic C Chow; Kalpana J Kallianpur; Maegen Walker; Scott Souza; Louie Mar A Gangcuangco; Beau K Nakamoto; Francis D Pien; Timothy Duerler; Linda Castro; Lorna Nagamine; Bruce Soll
Journal:  HIV Clin Trials       Date:  2018-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.